Fundamental analysis · SEC EDGAR · TTM through 30/06/2026
IDXX · Nasdaq · Healthcare
Fundamental quality
84
out of 100
Idexx Laboratories Inc fits the profile of a quality compounder: it pairs high return on capital (ROE 70.7%) with wide margins (net margin 25%) and a business that keeps growing (9.9% a year). On fundamental quality it scores 84 out of 100, profiling it as a company with solid fundamentals. Its weakest area is its growth (revenue +9.9%/yr). Whether it's cheap or expensive depends on the current price, which you can compute in the tool.
IDEXX Laboratories dominates veterinary diagnostics: the analyzers and tests clinics use to examine the blood and health of dogs and cats. Its model is textbook: place the device, then live off the consumables it requires forever.
EPS growth: 13% · Revenue growth: 9.9%
Net margin: 25% · ROE: 70.7% · ROIC: 62.6%
Net debt/EBITDA: 0.16x · FCF: 27.5%
Source: SEC EDGAR · TTM through 30/06/2026
The score combines growth, profitability and financial strength. Here its financial strength weighs in its favor, while its growth drags it down the most.
Percentile against the other 57 Healthcare companies in our coverage: how far it beats them on each metric (100 = best in sector).
Computed from the daily dataset scores. A high percentile places the company among the best in its sector on that metric; it is not a buy recommendation.
Key concepts
What do these metrics mean? Fundamental analysis · What is the P/E · What is EPS · What is ROE · Net & gross margin · Free cash flow
| Year | Revenue | Net income | Free cash flow | Net debt |
|---|---|---|---|---|
| 2020 | 2,707 | 582 | 541 | 525 |
| 2021 | 3,215 | 745 | 636 | 706 |
| 2022 | 3,367 | 679 | 394 | 657 |
| 2023 | 3,661 | 845 | 773 | 244 |
| 2024 | 3,898 | 888 | 808 | 329 |
| 2025 | 4,304 | 1,059 | 1,057 | 270 |
Between 2020 and 2025, revenue went from $2,707M to $4,304M (+59%) and net income went from $582M to $1,059M (+82%). Meanwhile, its margins have widened (from 21% to 25%).
Annual figures in millions of U.S. dollars ($M) per SEC filings. Net debt is total debt minus cash.
Latest results
Figures for the half-year ended June 30, 2026, versus the half-year ended June 30, 2025 (SEC filings):
Automatic comparison between the two most recent periods filed with the SEC. One quarter doesn't make a trend: read it alongside the historical evolution above.
This company doesn't pay a dividend: it reinvests all its earnings back into the business.
Open your account in minutes with regulated brokers and buy U.S. and European stocks from small amounts. No paperwork.
The serious investor's standard
Open free account →Anyone who wants low commissions and access to almost any market in the world.
Popular in the U.S.
Open free account →Anyone investing in the U.S. who wants a powerful, commission-free stock app.
Investing carries risk of loss.
Is Idexx Laboratories Inc cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Is Idexx Laboratories Inc a good company to invest in?
In terms of business quality, Idexx Laboratories Inc scores 84 out of 100 in our analysis, placing it as a company of high fundamental quality. That said, this isn't a recommendation: whether it's a good investment also depends on its current price and your goals.
Is Idexx Laboratories Inc a profitable company?
Very. Idexx Laboratories Inc shows a net margin of 25% and an ROE of 70.7%, typical of a highly profitable business.
Does Idexx Laboratories Inc have a lot of debt?
Not particularly. Its net debt is 0.16 times its EBITDA, a low level.
Is Idexx Laboratories Inc growing?
Its revenue has grown 9.9% annualized in recent years and its earnings per share 13%, and without interruption since 2020.
Does Idexx Laboratories Inc generate cash?
Yes. It converts about 27.5% of its revenue into free cash flow, and has done so positively year after year.
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
More Healthcare companies
Medline (MDLN) · Tenet Healthcare (THC) · Universal Health Services (UHS) · Teva Pharmaceutical Industries (TEVA) · Davita (DVA) · Henry Schein (HSIC) · see more →
The best Healthcare stocks by our model →
Compare Idexx Laboratories Inc with 500+ companies in the screener →
Who's behind the methodology and model · how the score is computed
Data: see Idexx Laboratories Inc's filings on EDGAR
Spotted a figure that looks wrong? Report it and we'll review it.